Literature DB >> 12142554

HER/erbB receptors as therapeutic targets of immunotoxins in human rhabdomyosarcoma cells.

Cinzia Ricci1, Letizia Polito, Patrizia Nanni, Lorena Landuzzi, Annalisa Astolfi, Giordano Nicoletti, Ilaria Rossi, Carla De Giovanni, Andrea Bolognesi, Pier-Luigi Lollini.   

Abstract

Human rhabdomyosarcoma cells express HER/erbB growth factors receptors. Receptors belonging to this family are overexpressed and play a role in many types of epithelial and neural cancer and have been selected as targets for cancer therapy. In this paper EGF-R, HER-2 and HER-3 receptors were tested as therapeutic targets of immunotoxins in human rhabdomyosarcoma. Rhabdomyosarcoma cells were treated with indirect immunotoxins consisting in primary specific murine monoclonal antibodies recognizing EGF-R, HER-2 and HER-3 followed by secondary F(ab')2 antimouse immunoglobulin linked to saporin-S6, a type 1 ribosome-inactivating protein (RIP) from the seeds of Saponaria officinalis. The indirect immunotoxin targeting EGF-R caused a significant inhibition in cell growth and protein synthesis and a strong increase in apoptosis in rhabdomyosarcoma cells, whereas indirect immunotoxins against HER-2 and HER-3 were ineffective. The toxic activity of anti-EGF-R immunotoxin was also observed on rhabdomyosarcoma cells expressing low level of EGF-R. EGF-R could be a novel therapeutic target of immunotoxins in human rhabdomyosarcoma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12142554     DOI: 10.1097/00002371-200207000-00003

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  7 in total

1.  In vitro effects and ex vivo binding of an EGFR-specific immunotoxin on rhabdomyosarcoma cells.

Authors:  Judith Niesen; Hannes Brehm; Christoph Stein; Nina Berges; Alessa Pardo; Rainer Fischer; Andre Ten Haaf; Stefan Gattenlöhner; Mehmet K Tur; Stefan Barth
Journal:  J Cancer Res Clin Oncol       Date:  2014-11-30       Impact factor: 4.553

2.  Selective Targeting of Myoblast Fusogenic Signaling and Differentiation-Arrest Antagonizes Rhabdomyosarcoma Cells.

Authors:  Valerie A Granados; Usha Avirneni-Vadlamudi; Pooja Dalal; Samuel R Scarborough; Kathleen A Galindo; Priya Mahajan; Rene L Galindo
Journal:  Cancer Res       Date:  2019-07-22       Impact factor: 12.701

3.  Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells.

Authors:  Laura Menotti; Giordano Nicoletti; Valentina Gatta; Stefania Croci; Lorena Landuzzi; Carla De Giovanni; Patrizia Nanni; Pier-Luigi Lollini; Gabriella Campadelli-Fiume
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-20       Impact factor: 11.205

4.  Targeting the insulin-like growth factor pathway in rhabdomyosarcomas: rationale and future perspectives.

Authors:  Ana Sofia Martins; David Olmos; Edoardo Missiaglia; Janet Shipley
Journal:  Sarcoma       Date:  2011-03-03

Review 5.  Immunotoxins and other conjugates containing saporin-s6 for cancer therapy.

Authors:  Letizia Polito; Massimo Bortolotti; Manuela Pedrazzi; Andrea Bolognesi
Journal:  Toxins (Basel)       Date:  2011-06-22       Impact factor: 4.546

Review 6.  The importance of being dead: cell death mechanisms assessment in anti-sarcoma therapy.

Authors:  Santiago Rello-Varona; David Herrero-Martín; Laura Lagares-Tena; Roser López-Alemany; Núria Mulet-Margalef; Juan Huertas-Martínez; Silvia Garcia-Monclús; Xavier García Del Muro; Cristina Muñoz-Pinedo; Oscar Martínez Tirado
Journal:  Front Oncol       Date:  2015-04-07       Impact factor: 6.244

Review 7.  Bouganin, an Attractive Weapon for Immunotoxins.

Authors:  Massimo Bortolotti; Andrea Bolognesi; Letizia Polito
Journal:  Toxins (Basel)       Date:  2018-08-08       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.